转移性去势抵抗性前列腺癌的新型内分泌治疗研究进展  

Research progress of novel hormone therapy for metastatic castration-resistant prostate cancer

作　　者：杨明乾 苏佳豪 梁朝龙 王坚 YANG Mingqian;SU Jiahao;LIANG Chaolong;WANG Jian(Department of Urology,Affiliated Hospital of Guangdong Medical University,Zhanjiang,Guangdong 524000,China)

机构地区：[1]广东医科大学附属医院泌尿外科,广东湛江524000

出　　处：《安徽医药》2025年第3期445-450,共6页Anhui Medical and Pharmaceutical Journal

摘　　要：转移性去势抵抗性前列腺癌(mCRPC)是极大影响前列腺癌病人预后的一个疾病晚期阶段。此阶段,雄激素受体(AR)信号通路与mCRPC发生发展密切相关,同时也是治疗靶点,所以此阶段抗雄激素治疗仍是有效的。近些年,许多新型内分泌治疗(NHT)药物被陆续研发出来,给mCRPC病人提供了更多比传统治疗疗效更优的治疗方案。与此同时,也有研究多次报道NHT药物因肿瘤异质性和耐药等原因,导致疗效欠佳,且对于NHT药物不同联合治疗方案和用药顺序尚存在争议。该研究就转移性去势抵抗性前列腺癌的NHT治疗、基于NHT联合治疗以及基于NHT序贯治疗的近年来研究现况和进展作一综述。Metastatic castration-resistant prostate cancer(mCRPC)is an important disease stage that seriously affects the prognosis of patients with prostate cancer.At this stage,androgen receptor(AR)signaling pathway is closely related to the occurrence and development of mCRPC and is also a therapeutic target.Therefore,anti-androgen therapy is still effective at this stage.In recent years,many novel hormone therapy(NHT)drugs have been developed successively,providing mCRPC patients with more effective treatment than the traditional treatment.At the same time,it has been reported in many studies that NHT drugs have poor efficacy due to tumor heterogeneity and drug resistance.And there is still controversy over different combination therapy schemes and medication sequence of NHT drugs.In this review,the current status and progress of NHT therapy,NHT combination therapy and NHT sequential therapy in metastatic castration-resistant prostate cancer in recent years are reviewed.

关 键 词：去势抵抗性前列腺癌 新型内分泌治疗 雄激素受体 转移性前列腺癌 阿比特龙 恩杂鲁胺 

分 类 号：R73[医药卫生—肿瘤]